Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
|
|
- Georgiana Lydia Bennett
- 5 years ago
- Views:
Transcription
1 European Heart Journal (2007) 28, doi: /eurheartj/ehm016 Clinical research Coronary heart disease Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial Chadwick D. Miller 1 *, Anindita Banerjee 2, Kenneth W. Mahaffey 3, Michael C. Kontos 4, Gregory Fermann 5, Charles V. Pollack Jr. 6, Elliott Antman 7, Philip Aylward 8, Shaun G. Goodman 9, Renato Santos 10, James J. Ferguson 11, Robert M. Califf 3, and James W. Hoekstra 1 1 Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA; 2 Department of Statistics, North Carolina State University, Raleigh, NC, USA; 3 Duke Clinical Research Institute, Durham, NC, USA; 4 VCU Medical Center, Virginia Commonwealth University, Richmond, VA, USA; 5 Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA; 6 Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia, PA, USA; 7 Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA; 8 Flinders Medical Centre, Bedford Park, South Australia, Australia; 9 Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada; 10 Section of Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; and 11 Texas Heart Institute, Houston, TX, USA Received 3 November 2006; revised 17 January 2007; accepted 15 February 2007; online publish-ahead-of-print 3 April 2007 See page 1043 for the editorial comment on this article (doi: /eurheartj/ehm083) KEYWORDS Evolving myocardial infarction; Troponin; Initial treatment; Outcomes Aims Patients with myocardial infarction (MI) presenting immediately after symptom onset may be treated less aggressively due to their non-elevated troponin status. We compared the initial treatment and clinical outcomes of patients presenting with evolving MI (EMI) with those presenting with MI. Methods and results This study analysed data from the Superior Yield of the New strategy of Enoxaparin, Revascularisation, and Glycoprotein IIb/IIIa inhibitors (SYNERGY) trial, which enrolled patients meeting at least two of the following: age60 years, elevated cardiac biomarkers, or ST-segment changes. Patients were stratified by troponin results obtained within 12 h of presentation: EMI [initial troponin (2), second troponin (þ)], MI [initial troponin (þ)], and no MI at enrolment [first and second troponin (2)]. Comparisons were made using Wilcoxon rank-sum and x 2 tests. Of the 8309 patients with complete data, 5503 (66%) had MI, 1686 (20%) had EMI, and 1120 (13%) had no MI. Treatment patterns prior to enrolment were similar among EMI and MI patients [aspirin (88 vs. 86%), beta-blockers (62 vs. 61%), heparin (83 vs. 81%), and glycoprotein IIb/IIIa inhibitors (23 vs. 24%)]. Similar rates of percutaneous coronary intervention (48 vs. 50%) and coronary artery bypass grafting (21 vs. 22%) were seen after enrolment. Patients presenting with MI had a higher rate of death or recurrent MI compared with patients with EMI [16 vs. 13%, adjusted OR 1.22 (95% CI 1.04, 1.44)]. Conclusion Initial treatment patterns were similar among patients with EMI and MI in the SYNERGY trial. Patients with EMI had lower rates of death or re-infarction at 30 days compared with patients presenting with positive troponin results. Introduction Emergency department (ED) patients with chest pain and presumed acute coronary syndrome (ACS) are stratified according to risk using information derived from the history, physical examination, electrocardiogram (ECG), and cardiac biomarkers. According to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, high-risk criteria for adverse outcomes in patients with ACS include positive biomarkers, ST-segment deviation, advanced age, arrhythmias, haemodynamic instability, congestive heart failure (CHF), ongoing rest pain, and an * Corresponding author. Tel: þ ; fax: þ address: cmiller@wfubmc.edu accelerated pattern of angina. Patients meeting high-risk criteria should receive both aggressive pharmacological therapy and an early invasive management strategy. 1 Of the high-risk ACS criteria, positive biomarkers particularly elevated troponin are especially significant. Elevated troponin values signify that myocardial necrosis has occurred, offer an objective determinant that ACS is present, 2 and correlate with mortality. 1,3,4 Furthermore, clinical trials indicate that patients with elevated serum troponin levels benefit most from aggressive treatment. 5 7 However, troponin values do not immediately become abnormal after the onset of myocardial infarction (MI). Cell membrane rupture must occur before cardiac biomarkers are released, making detection in the blood possible; this often requires 6 8 h. Thus, patients presenting & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 1080 C.D. Miller et al. within 6 8 h of symptom onset initially may have negative cardiac biomarkers, delaying early recognition of MI and the use of aggressive therapy. The initial care and outcomes of patients presenting with MI and initially negative cardiac biomarkers have not been well described. We analysed data from the Superior Yield of the New strategy of Enoxaparin, Revascularisation, and Glycoprotein IIb/IIIa inhibitors (SYNERGY) trial 8 to compare the treatment patterns and outcomes of patients with evolving MI (EMI) to patients with MI. Methods Study design This investigation is a secondary analysis of data collected during the SYNERGY trial. Enrolling centres obtained institutional review board or Ethics Committee approval for patient enrolment, and all patients provided written consent for participation. The institutional review board of Wake Forest University School of Medicine has approved this analysis. Study setting and population Details of the SYNERGY trial have been previously reported in detail. 8,9 In brief, patients presenting to one of 467 participating sites in 12 countries with ischaemic symptoms of at least 10 min duration within the previous 24 h were enrolled if they met two of three inclusion criteria: age60 years, troponin or creatinine kinase-mb elevation above the upper limit of normal for the local laboratory, or definitive ST-segment changes on 12-lead ECG. Patients in this trial were randomized to receive unfractionated heparin (UFH) or enoxaparin. The use of ACC/AHA guidelines-recommended therapies and procedures, including aspirin, glycoprotein (GP) IIb/IIIa inhibitors, and early cardiac catheterization, were encouraged. Patients were followed for 1 year to determine the outcomes. Study protocol This analysis evaluated data from patients with two troponin assay results available within 12 h of presentation or one positive troponin result drawn within 12 h of presentation. Subjects who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) surgery within 12 h of presentation and did not have a prior positive troponin, who only had one normal troponin result within 12 h of presentation, and who had incomplete biomarker data were excluded. Included patients were divided into three groups. (1) Evolving MI. Patients were considered to have an EMI if their initial troponin result was below the institutional limit for normal and was followed by an additional assay that was above the institutional limit for normal within 12 h of hospital arrival; also, if PCI or CABG was performed, it was after the positive troponin. (2) MI at presentation. Patients were considered to have an MI at presentation if their initial troponin assay was above the institutional upper limit of normal and was obtained within 12 h of hospital arrival; if PCI or CABG was performed, it was after the positive troponin. (3) No MI at presentation. PatientswereconsideredtohavenoMIat presentation if at least two troponin results were available within 12 h of hospital arrival and all were negative; these patients also did not undergo PCI or CABG within 12 h of hospital arrival. Measurements and outcome measures Initial medical therapy Medical treatments administered between the time of hospital arrival and enrolment were recorded on the case report form. These included treatment with aspirin, beta-receptor antagonists, enoxaparin, UFH, clopidogrel, and GP IIb/IIIa inhibitors. Clinical outcomes The primary efficacy outcome for this study was 30-day death or recurrent MI as described previously. 8,9 Patients with MI at enrolment were not considered in the composite outcome to have recurrent infarction unless the definition of recurrent infarction was met. Secondary endpoints included the use of catheterization and revascularization procedures, as well as the time to each of these procedures. Statistical methods Data are presented as medians with 25th and 75th inter-quartiles for continuous variables and as frequencies with percentages for discrete variables. Statistical comparisons were made among the EMI and MI groups. All modelling also included the no-mi group. Univariate analyses were performed using Wilcoxon rank-sum test for ordinal measures and the Pearson s x 2 test for dichotomous measures. These same tests were used when comparing the two groups for the procedural factors. Comparisons between the two MI groups for the efficacy endpoints were performed using logistic regression modelling techniques. Multivariable models had been developed previously for mortality within 30 days of randomization, re-infarction within 30 days of randomization, and death or MI within 30 days of randomization. Characteristics found to be statistically significant in predicting death alone were smoking status, age, weight, region of enrolment, creatinine, rales, pulse, t-wave inversion, treatment, and an interaction term of treatment and current smoking. To predict MI by 30 days post-randomization, age, sex, height, race, region of enrolment, diabetes, smoking status, pulse, creatinine, and prior MI were found to be statistically significant. Lastly, age, sex, region of enrolment, height, race, diabetes, smoking status, pulse, creatinine, and prior MI were significant predictors of death or MI within 30 days of randomization. EMI, MI, and no-mi classifications were then added to these models to calculate adjusted results. Two-sided tests were run using a P-value of 0.05 to determine the statistical significance. As this is a hypothesis-generating manuscript, no adjustments were made to the pair-wise comparisons. These results are to be used to identify areas for further analyses and not as confirmatory results. Statistical software was used for the analyses (SAS Institute, v. 8.2, Cary, NC, USA). Results The SYNERGY trial included data from 9978 patients enrolled at 467 centres in 12 countries. Patients were excluded from our analysis due to missing troponin values and times within 12 h (n ¼ 1540), missing revascularization information (n ¼ 2), PCI or CABG prior to a positive troponin (n ¼ 78), and revascularization occurring prior to the negative troponin value within 12 h in the no-mi group (n ¼ 46), leaving 8312 (83%) satisfying our inclusion criteria. Excluded patients were statistically similar to included patients with respect to prior MI, prior CABG, prior CHF, and the outcome measures of death, MI, and their composite within 30 days. Excluded patients were significantly more likely to have ST-segment depression (60 vs. 54%) and be enrolled based on age and ECG changes (37 vs. 12%). Of 8312 included patients, 5597 (66%) had MI at enrolment, 1707 (20%) had an EMI, and 1008 (13%) had no MI at enrolment. Baseline characteristics of these groups are shown in Table 1. Compared with MI patients, EMI patients were similar in most demographic categories including age.60 years (both 74%), prior MI (28 vs. 27%), diabetes
3 Treatment patterns in patients with EMI 1081 Table 1 Demographics Overall N ¼ 8312 MI N ¼ 5597 EMI N ¼ 1707 No MI N ¼ 1008 Age.60, 6256/8312 (75.3) 4127/5597 (73.7) 1262/1707 (73.9) 867/1008 (86.0) Female sex, 2757/8312 (33.2) 1818/5597 (32.5) 530/1707 (31.0) 409/1008 (40.6) White race, 7170/8312 (86.3) 4921/5597 (86.1) 1477/1707 (86.5) 872/1008 (86.5) Medical history Prior MI, 2311/8286 (27.9) 1502/5582 (26.9) 481/1701 (28.3) 328/1003 (32.7) Prior CABG, 1372/8307 (16.5) 827/5593 (14.8) 313/1706 (18.3) 232/1008 (23.0) Prior CHF, 778/8311 (9.4) 540/5596 (9.6) 143/1707 (8.4) 95/1008 (9.4) Prior hypertension, 5597/8312 (67.3) 3747/5597 (66.9) 1106/1707 (64.8) 744/1008 (73.8) Prior stroke, 416/8312 (5.0) 286/5597 (5.1) 71/1707 (4.2) 59/1008 (5.9) Hypercholesterolaemia, 4851/8262 (58.7) 3320/5561 (57.9) 1001/1698 (59.0) 630/1003 (62.8) Diabetes, 2414/8312 (29.0) 1624/5597 (29.0) 465/1707 (27.2) 325/1008 (32.2) Tobacco use, 4961/8307 (59.7) 3396/5593 (60.7) 1023/1707 (59.9) 542/1007 (53.8) Prior angina, 3684/8311 (44.3) 2422/5597 (43.3) 704/1706 (41.3) 558/1008 (55.4) ST-depression on initial ECG, 4477/8298 (54.0) 2882/5585 (51.6) 894/1706 (52.4) 701/1007 (69.6) Enrolment criteria Age.60, (þ) ECG, (þ) biomarkers a, 3797/8108 (46.8) 2918/5485 (53.2) 738/1672 (44.1) 141/951 (14.8) Age.60, (2) ECG, (þ) biomarkers a, 1729/8108 (21.3) 1218/5485 (22.2) 390/1672 (23.3) 121/951 (12.7) Age.60, (þ) ECG, (2) biomarkers a, 955/8108 (11.8) 154/5485 (2.8) 176/1672 (10.5) 625/951 (65.7) Age,60, (þ) ECG, (þ) biomarkers a, 1627/8108 (20.1) 1195/5485 (21.8) 368/1672 (22.0) 64/951 (6.7) Time from symptom onset to hospital 7050, 3.1 (1.4, 7.1) 4841, 4.0 (1.7, 8.9) 1428, 1.7 (1.0, 3.1) 781, 2.6 (1.2, 6.0) arrival (h), N, median (Q1, Q3) Time from hospital arrival to 6796, 8.2 (3.6, 15.2) 4674, 6.7 (3.2, 14.0) 1373, 13.2 (8.0, 18.3) 749, 6.6 (2.9, 14.6) enrolment (h), N, median (Q1, Q3) TIMI risk score, N, median (Q1, Q3) 8312, 4 (3, 5) 5297, 4 (3, 5) 1707, 4 (3, 5) 1008, 4 (3, 5) PURSUIT risk score, N, median (Q1, Q3) 7862, 14 (13, 15) 5296, 14 (13, 15) 1626, 13 (12, 14) 940, 13 (12, 14) CABG, coronary artery bypass grafting; CHF, congestive heart failure; ECG, electrocardiogram; EMI, evolving myocardial infarction; MI, myocardial infarction; PURSUIT, Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy; TIMI, Thrombolysis In Myocardial Infarction. a Includes elevated creatine kinase-mb and/or troponin results. mellitus (27 vs. 29%), and ST-segment depression on presenting ECG (both 52%). Enrolment criteria varied by group. EMI patients were less likely than MI patients to be enrolled based upon age.60, ECG changes, and elevated biomarkers (troponin or creatine kinase-mb). However, EMI patients were more likely to be enrolled based upon age.60 and ECG changes with non-elevated biomarkers. EMI patients presented sooner after symptom onset than did MI patients (median 1.7 vs. 4.0 h) yet were enrolled later after presentation (median 13.2 vs. 6.7 h). The subset of EMI patients enrolled based upon age.60 and ECG changes had the shortest time from symptom onset to enrolment [median 5.8 h (Q1 3.4 h, Q h)]. Medical therapies provided are displayed in Table 2. Prior to enrolment, similar usage patterns for pharmacological therapies were seen among EMI and MI patients, including aspirin (88 vs. 86%), beta-blockers (62 vs. 61%), heparin [either low-molecular-weight heparin or unfractionated (80 vs. 77%)], clopidogrel (26 vs. 27%), and GP IIb/IIIa inhibitors (23 vs. 24%). Medical therapies and in-hospital procedures during the baseline hospitalization were similar among EMI and MI groups (Table 3). Clinical outcomes of 30-day death, re-infarction, and the composite of these measures are shown in Table 4. Among groups, MI patients had the highest incidence of the composite outcome (15.9% MI vs. 12.9% EMI, unadjusted OR 1.27, 95% CI 1.09, 1.49) and remained statistically different from the EMI group after adjustment [adjusted OR 1.22 (95% CI 1.04, 1.43)]. This finding was driven by a higher rate of both death and re-infarction among MI patients. Patients with EMI had better 30-day composite outcomes in both SYNERGY treatment assignments enoxaparin [MI 15.4% vs. EMI 13.8%, OR 1.10 (95% CI 0.88, 1.38)] and heparin [MI 16.3% vs. EMI 11.9%, OR 1.36 (95% CI 1.07, 1.72)]. Discussion The incorporation of troponin assays into clinical practice has changed the triage of patients with chest pain. Elevated troponin values correlate with mortality 1,3,4 and help identify a subset of patients who will benefit from the most aggressive therapies. 5 7 However, a prominent limitation to these tests is the time it takes for troponin to become released in the serum 6 8 h after MI. Fortunately, other features besides cardiac biomarkers have proved useful in the risk stratification of patients with chest pain. The ACC/AHA guidelines 1 list 11 criteria that place patients at high risk for short-term death or infarction, only one of which is related to cardiac biomarkers. The extent to which these other elements such as medical history, physical examination findings, and ECG results are used to guide treatment decisions is largely unknown.
4 1082 C.D. Miller et al. Table 2 Medical treatment during hospitalization Treatment Total MI EMI No MI Aspirin Prior to enrolment, 7117/8312 (85.6) 4783/5597 (85.5) 1497/1707 (87.8) 837/1008 (83.0) During baseline hospitalization, 7915/8312 (95.2) 5353/5597 (95.6) 1623/1707 (95.1) 939/1008 (93.2) Clopidogrel Prior to enrolment, 2195/8312 (26.4) 1501/5597 (26.8) 446/1707 (26.1) 248/1008 (24.6) During baseline hospitalization, 5300/8312 (63.8) 3657/5597 (65.3) 1105/1707 (64.7) 538/1008 (53.4) Beta-blocker Prior to enrolment, 5042/8312 (60.7) 3394/5597 (60.6) 1058/1707 (62.0) 590/1008 (58.5) During baseline hospitalization, 7200/8312 (86.6) 4895/5597 (87.5) 1481/1707 (86.8) 824/1008 (81.7) Heparin (LMWH or unfractionated) Prior to enrolment, 6310/8312 (75.9) 4306/5597 (76.9) 1364/1707 (79.9) 640/1008 (63.5) GP IIb/IIIa inhibitor Prior to enrolment, 1835/8287 (22.1) 1313/5582 (23.5) 398/1704 (23.4) 124/1001 (12.4) During baseline hospitalization: peri-procedural, 2674/3908 (68.4) 1913/2776 (68.9) 558/816 (68.4) 203/316 (64.2) EMI, evolving myocardial infarction; GP, glycoprotein; LMWH, low-molecular-weight heparin. Table 3 In-hospital procedures Catheterization Total MI EMI No MI In-hospital post-rand diagnostic 7664/8312 (92.2) 5190/5597 (92.7) 1588/1707 (93.0) 886/1008 (87.9) catheterization, Hours from enrolment to first 7617, 21.8 (7.0, 43.9) 5164, 21.3 (6.3, 43.3) 1556, 23.1 (7.7, 45.9) 877, 22.5 (14.2, 42.9) catheterization, N, median (Q1, Q3) In-hospital revascularization In-hospital CABG, 1594/8311 (19.2) 1131/5597 (20.2) 332/1706 (19.5) 131/1008 (13.0) Hours from enrolment to 1590, 90.5 (44.7, 166.6) 1131, 89.9 (44.7, 164.2) 329, 93.4 (44.1, 187.8) 130, 90.5 (44.1, 163.3) CABG, N, median (Q1, Q3) PCI during baseline and 3908/8312 (47.0) 2776/5597 (49.6) 816/1707 (47.8) 316/1008 (31.3) post-rand hospitalization, Hours from enrolment to first PCI, N, median (Q1, Q3) 3906, 22.9 (7.5, 49.1) 2776, 22.2 (6.6, 48.4) 815, 24.1 (7.4, 49.7) 315, 25.9 (18.6, 52.9) CABG, coronary artery bypass grafting; EMI, evolving myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention. This analysis examines the treatments administered to patients with EMI prior to enrolment in the SYNERGY clinical trial. The results demonstrate that the initial treatment patterns of patients presenting with EMI are similar to those presenting with MI. In fact, only minor differences in use were seen among EMI and MI groups for all guideline-recommended therapies, including aspirin, heparin, beta-blockers, clopidogrel, and GP IIb/IIIa inhibitors. These aggressive treatment patterns suggest that clinicians used and acted upon other high-risk features besides troponin values. These results also demonstrate that subjects with EMI have lower death and re-infarction rates compared with patients presenting with MI. Examining this finding further, EMI patients arrived earlier than MI patients (1.7 vs. 4.0 h) and both groups received similar treatments. Thus, EMI patients received aggressive, guideline-recommended care earlier in their course of infarction compared with those presenting with MI. It is likely that this early hospitalization and aggressive therapy translates into a decreased rate of adverse events. Analysis of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) registry by Roe et al. 10 suggests that treatment patterns among EMI and MI patients are similar in the first 24 h. In this analysis, subjects with initially negative troponin values that subsequently turned positive received treatments in the first 24 h similar to that received by subjects with initially positive troponin results. The present analysis from the SYNERGY trial builds upon the CRUSADE results by examining therapy earlier in the hospital course and suggests that the similarities in care begin long before the 24 h mark. As such, the care patterns described in the SYNERGY trial are more likely to reflect therapies ordered or administered in the ED. Risk stratification of patients with chest pain utilizes information available at one moment in time to estimate the probability of cardiac disease and the likelihood of adverse cardiac events. Using these estimates, clinicians can adjust treatment regimens according to risk. Once riskstratified, the EMI patients in the SYNERGY trial were a highrisk cohort, and physicians were correct in treating them as
5 Treatment patterns in patients with EMI 1083 Table 4 Adjusted clinical outcomes of evolving myocardial infarction vs. myocardial infarction patients Outcomes Total MI EMI No MI MI vs. EMI adjusted OR (95% CI) Composite 30-day death or re-infarction Total, 1197/8308 (14.4) 888/5597 (15.9) 220/1706 (12.9) 89/1008 (8.8) 1.22 (1.04, 1.43) Enoxaparin, 590/4131 (14.3) 428/2773 (15.4) 121/877 (13.8) 41/481 (8.5) 1.10 (0.88, 1.38) UFH, 607/4180 (14.5) 460/2824 (16.3) 99/829 (11.9) 48/527 (9.1) 1.36 (1.07, 1.72) 30-day death Total, 268/8312 (3.2) 209/5597 (3.7) 42/1707 (2.5) 17/1008 (1.7) 1.48 (1.04, 2.11) Enoxaparin, 141/4131 (3.4) 107/2773 (3.9) 28/877 (3.2) 6/481 (1.3) 1.18 (0.76, 1.84) UFH, 127/4181 (3.0) 102/2824 (3.6) 14/830 (1.7) 11/527 (2.1) 2.17 (1.19, 3.96) 30-day re-infarction Total, 1017/8312 (12.2) 745/5597 (13.3) 194/1707 (11.4) 78/1008 (7.7) 1.16 (0.98, 1.38) Enoxaparin, 492/4131 (11.9) 353/2772 (12.7) 102/877 (11.6) 37/481 (7.7) 1.09 (0.86, 1.39) UFH, 525/4181 (12.6) 392/2824 (13.9) 92/830 (13.9) 41/527 (7.8) 1.22 (0.96, 1.55) CI, confidence interval; EMI, evolving myocardial infarction; MI, myocardial infarction; OR, odds ratio. such despite their negative troponin status. Among riskstratification systems, age, elevated cardiac biomarkers, and ischaemic ECG findings consistently have been found to identify a high-risk cohort of patients among those who present with possible MI. Most of our EMI population had at least two of those criteria, with many having all three. Boersma et al. 11 developed the Platelet GP IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) risk score. Elements of the PURSUIT score include vital sign abnormalities, age, sex, Canadian Cardiovascular Society angina score, ST-segment depression, and heart failure on presentation. The PURSUIT risk score has the added advantage of distinguishing between patients presenting with unstable angina and MI and providing a different risk assessment for each. In this analysis, the group of patients with EMI had a median PURSUIT risk score of 13, correlating to almost a 20% 30-day rate of death or re-infarction. Similarly, the Thrombolysis In Myocardial Infarction (TIMI) risk score is a validated method for assigning risk of death, re-infarction, or urgent revascularization in patients with unstable angina and non ST-segment elevation MI. 12,13 Variables directly predictive of adverse outcomes include age, ST-segment changes, known coronary artery disease (CAD), risk factors for CAD, recent use of aspirin, and elevated cardiac biomarkers. The patients with EMI in this analysis had a median TIMI risk score of 4, correlating to a 14-day adverse event rate of 20% in patients from the TIMI 11b study 12 and a 30-day rate of 42% in patients prospectively evaluated by Bartholomew et al. 13 Finally, the ACC/AHA guidelines for management of patients with unstable angina and non ST-segment elevation MI 1 recommend using the criteria by Braunwald 14 to risk stratify. Under this risk-stratification system, 77% of our EMI patients would have met ACC/AHA high-risk criteria based upon ECG findings alone. Limitations Our data were collected as part of the SYNERGY trial, and, thus, the demographics of our groups closely resemble the inclusion criteria. The inclusion criteria for SYNERGY were designed to evaluate patients with high-risk unstable angina or non ST-segment elevation MI. These strict criteria excluded many patients with EMI due to negative cardiac biomarkers at the time of initial presentation. Our sample of EMI patients likely represents a unique subset of higherrisk patients those who met the other two inclusion criteria of age60 or ST-segment changes at the time of enrolment. Additionally, patients with EMI had a longer elapsed time from presentation to enrolment compared with those presenting with MI. During that time, sicker patients could have been excluded, which could have affected the event rates. As such, the proportion and prognosis of patients with EMI in the general population cannot be ascertained from this study. In this clinical trial, high-risk patients received aggressive pharmacological care. However, the care patterns seen in this well-controlled clinical trial may not necessarily reflect those seen in real-world practice. In fact, in realworld practice, a disconnection between risk stratification and therapy for high-risk ACS patients exists. 15 Data from the CRUSADE registry demonstrate that higher-risk patients based on age, sex, chronic renal failure, diabetes, or risk score do not necessarily receive more aggressive therapy. 16,17 These patients are often excluded from clinical trials such as SYNERGY, and, as such, the results of this analysis cannot be used to measure compliance. Some patients enrolled in the SYNERGY trial could not be included in our analysis, predominantly due to missing biomarker data prior to enrolment. The recording of preenrolment troponin values was not mandatory and was routinely performed at some sites but not others. Although included and excluded patients seemed mostly similar with respect to demographics, the excluded group was much more likely to be enrolled based upon age and ECG criteria and have negative biomarkers at the time of enrolment. No differences were seen among these groups with respect to outcome events. It is possible that exclusion of these patients introduces selection bias. However, we feel this is less likely, and it more likely represents a characteristic of the site as opposed to a particular patient subgroup. However, the precise impact on our analysis is unknown. As a secondary analysis of a completed trial, it is not possible to adjust for all confounding variables. Although our clinical outcome differences are statistically significant, they should be prospectively validated and can only be hypothesis-generating at this point.
6 1084 C.D. Miller et al. Conclusions The results of this analysis demonstrate that patients with EMI are treated with fundamental and advanced therapies for ACS at a similar rate when compared with patients who are initially troponin-positive. These findings suggest that clinicians incorporate other elements of risk stratification when deciding on treatment regimens for troponinnegative patients. Patients with EMI demonstrated lower rates of death and re-infarction at 30 days compared with those who presented troponin-positive. Acknowledgements The SYNERGY trial was funded by sanofi-aventis. The authors would like to thank Amanda Stebbins of the Duke Clinical Research Institute (DCRI) for her statistical assistance with this manuscript. They would also like to acknowledge the editorial assistance of Amanda McMillan of the DCRI. Conflict of interest: The authors have the following conflicts of interest to disclose. K.W.M., E.A., P.A., S.G.G., J.J.F., and R.M.C. were supported by Research Grants, sanofi-aventis. K.W.M., M.K., C.V.P., P.A., S.G.G., J.J.F., and J.W.H. were supported by Speaker s Bureau, sanofi-aventis. K.W.M., M.K., C.V.P., P.A., S.G.G., J.J.F., and J.W.H. were supported by Consulting or Honoraria, sanofi-aventis. References 1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr ; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina.. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-st-segment elevation myocardial infarction summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40: The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21: Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335: Green GB, Beaudreau RW, Chan DW, DeLong D, Kelley CA, Kelen GD. Use of troponin T and creatine kinase-mb subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. Ann Emerg Med 1998;31: Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359: Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29: Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999; 354: SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292: The SYNERGY Executive Committee trial: study design and rationale. Am Heart J 2002;143: Roe MT, Peterson ED, Pollack CV Jr, Newby LK, Li Y, Christenson RH, Peacock WF, Fesmire FM, Diercks D, Kirk JD, Smith SC Jr, Ohman EM, Gibler WB ; CRUSADE Investigators. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non ST-segment elevation acute coronary syndromes. Ann Emerg Med 2005;45: Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000; 101: Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-st elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284: Bartholomew BA, Sheps DS, Monroe S, McGorray S, Smith K, Pepine CJ. A population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-st elevation myocardial infarction. Clin Cardiol 2004;27: Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE III, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90: Giugliano RP, Braunwald E. The year in non-st-segment elevation acute coronary syndromes. J Am Coll Cardiol 2005;46: Hoekstra JW, Roe MT, Peterson ED, Menon V, Mulgund J, Pollack CV, Miller C, Palabrica T, Harrington RA, Ohman EM, Gibler WB. Early glycoprotein IIb/IIIa inhibitor use for non ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med 2005;12: Ohman EM, Roe MT, Smith SC Jr, Brindis RG, Christenson RH, Harrington RA, Gibler WB, Peterson ED; CRUSADE Investigators. Care of non-st-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004; 148(Suppl. 5): S34 S39.
Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.062
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationPrognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris C T KASANUKI, MD, FJCC
C T Prognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris Hiroyuki Yukio Hiroshi TANAKA, MD TSURUMI, MD KASANUKI, MD, FJCC Abstract Objectives. The prognosis
More informationCRUSADE - A Roadmap for Change:
MARCH 2005 VOLUME 2 CRUSADE - A Roadmap for Change: 100,000 Patients Make a Difference Interim Analysis of the 100,000 Patients Enrollment Milestone March, 2005 Dear Colleagues: It is with great pleasure
More informationOriginal Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice
Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationThe Thrombolysis In Myocardial Infarction Risk Score in Unstable Angina/ Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)03019-x
More informationJournal of the American College of Cardiology Vol. 45, No. 6, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 6, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.11.055
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationClinical Investigations
Clinical Investigations The Usage Patterns of Cardiac Bedside Markers Employing Point-of-Care Testing for Troponin in Non-ST-Segment Elevation Acute Coronary Syndrome: Results from CRUSADE Address for
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationJournal of the American College of Cardiology Vol. 40, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationJournal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02824-3
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationINTRODUCTION. Key Words:
Original Article Acta Cardiol Sin 2017;33:377 383 doi: 10.6515/ACS20170126A Percutaneous Coronary Intervention Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome
More informationJournal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02970-4
More informationNEW CONCEPTS AND EMERGING TECHNOLOGIES FOR EMERGENCY PHYSICIANS
SEPTEMBER 2007 volume 5 C O L L A B O R AT E I N V E S T I G AT E E D U C AT E Use of Direct Thrombin Inhibitors for Treating Non-ST-Segment Elevation Acute Coronary Syndromes in Special Patient Groups:
More informationUtilization and Impact of Pre-Hospital Electrocardiograms for Patients With Acute ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 53, No. 2, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.030
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationPATIENTS PRESENTING WITH AN
ORIGINAL CONTRIBUTION The TIMI Risk Score for Unstable Angina/Non ST Elevation MI A Method for Prognostication and Therapeutic Decision Making Elliott M. Antman, MD Marc Cohen, MD Peter J. L. M. Bernink,
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02963-7
More informationUse of Guidelines-Recommended Management and Outcomes Among Women and Men With Low-Level Troponin Elevation Insights From CRUSADE
Use of Guidelines-Recommended Management and Outcomes Among Women and Men With Low-Level Troponin Elevation Insights From CRUSADE Sharif A. Halim, MD; Jyotsna Mulgund, MS; Anita Y. Chen, MS; Matthew T.
More informationORIGINAL INVESTIGATION. Clopidogrel to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge
ORIGINAL INVESTIGATION to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge Pierluigi Tricoci, MD; Matthew T. Roe, MD, MHS; Jyotsna Mulgund, MS; L. Kristin
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationDifferential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction
Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy
More informationCreatine kinase-mb elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
European Heart Journal (2004) 25, 313 321 Clinical research Creatine kinase-mb elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes M.T.
More informationPatients with acute coronary syndromes have a range of. Clinical Investigation and Reports
Clinical Investigation and Reports Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation Results From an International Trial of 9461 Patients Eric Boersma,
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationAntithrombotic Strategy in Non ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 6, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.03.015 Antithrombotic
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationCardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status
European Heart Journal (2000) 21, 1159 1166 doi:10.1053/euhj.1999.1986, available online at http://www.idealibrary.com on Cardiovascular risk and therapeutic benefit of coronary interventions for patients
More informationProspective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz,
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationEarly diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong
Hong Kong Journal of Emergency Medicine Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong CH Ho, W Cheng, G Chu, HF Ho Introduction: Cardiac
More informationIN patients with ST elevated myocardial infarction, ST segment resolution following
The Effect of Tirofiban on ST Segment Resolution in Patients With Non-ST Elevated Myocardial Infarction Özgür BAYTURAN, 1 MD, Ali Riza BILGE, 1 MD, Cevad SEKÜRI, 1 MD, Ozan ÜTÜK, 1 MD, Hakan TIKIZ, 1 MD,
More informationJournal of the American College of Cardiology Vol. 51, No. 18, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 51, No. 18, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.12.052
More informationJournal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01503-0 Acute
More informationJournal of the American College of Cardiology Vol. 39, No. 10, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 10, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01841-7
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNew Risk Score for Patients With Acute Chest Pain, Non ST-Segment Deviation, and Normal Troponin Concentrations A Comparison With the TIMI Risk Score
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.04.037
More informationREVIEW DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK. Edith A. Nutescu, PharmD * ABSTRACT INTRODUCTION
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD * ABSTRACT Acute coronary syndrome is a form of coronary artery disease, which has a broad range of clinical presentations.
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationUse of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 11, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.08.015 CLINICAL RESEARCH
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationRisk Assessment Models in Acute Coronary Syndromes and Their Applicability in Singapore
216 Review Article Risk Assessment Models in Acute Coronary Syndromes and Their Applicability in Singapore Chee Tang Chin, 1 MBChB (Edin), MRCP (UK), FAMS (Cardiol), Terrance SJ Chua, 1 MMed, FRCP, FAMS,
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationA Prior Myocardial Infarction: How Does it Affect Management and Outcomes in Recurrent Acute Coronary Syndromes?
A Prior Myocardial Infarction: How Does it Affect Management and Outcomes in Recurrent Acute Coronary Syndromes? Address for correspondence: Kim A. Eagle, MD University of Michigan Cardiovascular Center
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationBenefit of Early Invasive Therapy in Acute Coronary Syndromes A Meta-Analysis of Contemporary Randomized Clinical Trials
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.050
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris Desai A S, Solomon D H, Stone P H, Avorn J Record Status This is a critical abstract
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationORIGINAL INVESTIGATION. Recent Trends in the Care of Patients With Non ST-Segment Elevation Acute Coronary Syndromes
ORIGINAL INVESTIGATION Recent Trends in the Care of Patients With Non ST-Segment Elevation Acute Coronary Syndromes Insights From the CRUSADE Initiative Rajendra H. Mehta, MD, MS; Matthew T. Roe, MD, MHS;
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationCardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes The Potential Role of Early Percutaneous Revascularization
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00434-9 Cardiac
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationManaging Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics
Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics Robert L. Jesse, MD, PhD National Program Director for Cardiology Veterans Health Administration Washington, DC Chief, Cardiology
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationTime to Medical Management in Patients Presenting with Non-ST Elevation Myocardial Infarction: A Retrospective Analysis of Two Teaching Hospitals
ORIGINAL RESEARCH Time to Medical Management in Patients Presenting with Non-ST Elevation Myocardial Infarction: A Retrospective Analysis of Two Teaching Hospitals Darren R. Kagal 1 and Omid Salehian 2
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationCardiovascular diseases are the leading cause of morbidity and mortality
ORIGINAL ARTICLE Thrombolysis in myocardial infarction (TIMI) risk score validation in Saudi Arabia Saad Al-Bugami, Faisal Al-Husayni, Samer Alamri, Rakan Aljedaani, Mohammad Zwawy, Abdulaziz Al-Zahrani
More informationThe American College of Cardiology (ACC)/American
ACC/AHA Practice Guidelines ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non ST-Segment Elevation Myocardial Infarction 2002: Summary Article A Report of the American
More informationPractical Implementation of the Guidelines for Unstable Angina/Non ST-Segment Elevation Myocardial Infarction in the Emergency Department
AHA SCIENTIFIC STATEMENT Practical Implementation of the Guidelines for Unstable Angina/Non ST-Segment Elevation Myocardial Infarction in the Emergency Department W. Brian Gibler, MD, Chair Christopher
More informationPredictors of 90-day outcome in patients stabilized after acute coronary syndromes
European Heart Journal (2003) 24, 172 181 Predictors of 90-day outcome in patients stabilized after acute coronary syndromes L.K. Newby a *, M.V. Bhapkar a, H.D. White b, E.J. Topol c, F.C. Dougherty d,
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationThe Impact of For-Profit Hospital Status on the Care and Outcomes of Patients With Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 50, No. 15, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.012
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More informationCURRENT QUALITY IMPROVEment
ORIGINAL CONTRIBUTION Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non ST-Segment Elevation Acute Coronary Syndromes Karen P. Alexander, MD Anita Y. Chen, MS Matthew T. Roe,
More informationImpact of Delay to Angioplasty in Patients With Acute Coronary Syndromes Undergoing Invasive Management
Journal of the American College of Cardiology Vol. 55, No. 1, by the American College of Cardiology Foundation ISSN 735-97//$3. Published by Elsevier Inc. doi:.1/j.jacc.9.11.3 CLINICAL RESEARCH Invasive
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationOvercoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
More informationA cute coronary syndrome (ACS) is a broad
217 REVIEW Contemporary management of acute coronary syndrome G A Large... This review focuses on the modern management of the non- ST elevation acute coronary syndromes (unstable angina and non-st elevation
More informationAssociation of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative
Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative Trip J. Meine, MD, a Matthew T. Roe, MD, MHS, a Anita Y. Chen,
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More informationAnticoagulation therapy in acute coronary syndromes according to current guidelines
Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st
More informationProspective Validation of the Dante Pazzanese Risk Score in Non-ST- Segment Elevation Acute Coronary Syndrome
Prospective Validation of the Dante Pazzanese Risk Score in Non-ST- Segment Elevation Acute Coronary Syndrome Elizabete Silva dos Santos, Luiz Minuzzo, Roberta de Souza, Ari Timerman Instituto Dante Pazzanese
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationNew Guidelines for Evaluating Acute Coronary Syndrome
New Guidelines for Evaluating Acute Coronary Syndrome The American College of Cardiology and the American Heart Association [Clinician Reviews 11(1):73-86, 2001. 2001 Clinicians Publishing Group] Introduction
More informationInternational variation in invasive care of the elderly with acute coronary syndromes
European Heart Journal (2006) 27, 1558 1564 doi:10.1093/eurheartj/ehl067 Clinical research Coronary heart disease International variation in invasive care of the elderly with acute coronary syndromes Karen
More informationAwealth of research in acute coronary syndrome
CLINICAL TRIAL SUPPORT OF THE USE OF CRITICAL PATHWAYS IN IMPROVING PATIENT OUTCOMES Judy W. M. Cheng, PharmD, MPH, BCPS, FCCP * ABSTRACT Acute coronary syndrome (ACS) is a common condition encountered
More informationMethods The PARAGON-B trial
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial Kenneth W. Mahaffey, MD, a Matthew T. Roe, MD, a Christopher K. Dyke,
More informationKeywords Non ST-segment elevation ACS Antithrombotic therapy Glycoprotein IIb/IIIa inhibitor Tirofiban. Introduction
J Thromb Thrombolysis (2007) 24:241 246 DOI 10.1007/s19-007-0015-y Routine upstream versus selective down stream use of tirofiban in non-st elevation myocardial infarction patients scheduled for early
More informationCompliance with guidelines and 1-year mortality in patients with acute myocardial infarction: a prospective study
Publish-Ahead-of-Print published January 28, 2005 European Heart Journal doi:10.1093/eurheartj/ehi107 Clinical research Compliance with guidelines and 1-year mortality in patients with acute myocardial
More information